11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      User centered clinical decision support to implement initiation of buprenorphine for opioid use disorder in the emergency department: EMBED pragmatic cluster randomized controlled trial

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          To determine the effect of a user centered clinical decision support tool versus usual care on rates of initiation of buprenorphine in the routine emergency care of individuals with opioid use disorder.

          Design

          Pragmatic cluster randomized controlled trial (EMBED).

          Setting

          18 emergency department clusters across five healthcare systems in five states representing the north east, south east, and western regions of the US, ranging from community hospitals to tertiary care centers, using either the Epic or Cerner electronic health record platform.

          Participants

          599 attending emergency physicians caring for 5047 adult patients presenting with opioid use disorder.

          Intervention

          A user centered, physician facing clinical decision support system seamlessly integrated into user workflows in the electronic health record to support initiating buprenorphine in the emergency department by helping clinicians to diagnose opioid use disorder, assess the severity of withdrawal, motivate patients to accept treatment, and complete electronic health record tasks by automating clinical and after visit documentation, order entry, prescribing, and referral.

          Main outcome measures

          Rate of initiation of buprenorphine (administration or prescription of buprenorphine) in the emergency department among patients with opioid use disorder. Secondary implementation outcomes were measured with the RE-AIM (reach, effectiveness, adoption, implementation, and maintenance) framework.

          Results

          1 413 693 visits to the emergency department (775 873 in the intervention arm and 637 820 in the usual care arm) from November 2019 to May 2021 were assessed for eligibility, resulting in 5047 patients with opioid use disorder (2787 intervention arm, 2260 usual care arm) under the care of 599 attending physicians (340 intervention arm, 259 usual care arm) for analysis. Buprenorphine was initiated in 347 (12.5%) patients in the intervention arm and in 271 (12.0%) patients in the usual care arm (adjusted generalized estimating equations odds ratio 1.22, 95% confidence interval 0.61 to 2.43, P=0.58). Buprenorphine was initiated at least once by 151 (44.4%) physicians in the intervention arm and by 88 (34.0%) in the usual care arm (1.83, 1.16 to 2.89, P=0.01).

          Conclusions

          User centered clinical decision support did not increase patient level rates of initiating buprenorphine in the emergency department. Although streamlining and automating electronic health record workflows can potentially increase adoption of complex, unfamiliar evidence based practices, more interventions are needed to look at other barriers to the treatment of addiction and increase the rate of initiating buprenorphine in the emergency department in patients with opioid use disorder.

          Trial registration

          ClinicalTrials.gov NCT03658642.

          Related collections

          Most cited references58

          • Record: found
          • Abstract: not found
          • Book: not found

          Diagnostic and Statistical Manual of Mental Disorders

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Evaluating the public health impact of health promotion interventions: the RE-AIM framework.

            Progress in public health and community-based interventions has been hampered by the lack of a comprehensive evaluation framework appropriate to such programs. Multilevel interventions that incorporate policy, environmental, and individual components should be evaluated with measurements suited to their settings, goals, and purpose. In this commentary, the authors propose a model (termed the RE-AIM model) for evaluating public health interventions that assesses 5 dimensions: reach, efficacy, adoption, implementation, and maintenance. These dimensions occur at multiple levels (e.g., individual, clinic or organization, community) and interact to determine the public health or population-based impact of a program or policy. The authors discuss issues in evaluating each of these dimensions and combining them to determine overall public health impact. Failure to adequately evaluate programs on all 5 dimensions can lead to a waste of resources, discontinuities between stages of research, and failure to improve public health to the limits of our capacity. The authors summarize strengths and limitations of the RE-AIM model and recommend areas for future research and application.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence

              Cochrane Database of Systematic Reviews
                Bookmark

                Author and article information

                Contributors
                Role: associate professor
                Role: associate research scientist
                Role: professor
                Role: assistant professor
                Role: assistant professor
                Role: lecturer
                Role: assistant professor
                Role: associate professor
                Role: associate research scientist
                Role: senior biostatistician
                Role: instructor fellow
                Role: associate professor
                Role: assistant professor
                Role: research assistant
                Role: chief medical officer
                Role: chair
                Role: professor
                Journal
                BMJ
                BMJ
                BMJ-US
                bmj
                The BMJ
                BMJ Publishing Group Ltd.
                0959-8138
                1756-1833
                2022
                27 June 2022
                : 377
                : e069271
                Affiliations
                [1 ]Department of Emergency Medicine, Yale University School of Medicine, New Haven, CT, USA
                [2 ]Yale School of Public Health, New Haven, CT, USA
                [3 ]Department of Emergency Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA
                [4 ]Department of Emergency Medicine and Division of Health Care Delivery Research, Mayo Clinic, Rochester, MN, USA
                [5 ]Department of Emergency Medicine, University of Massachusetts Medical School, Springfield, MA, USA
                [6 ]Department of Emergency Medicine, University of Colorado, Aurora, CO, USA
                [7 ]Department of Emergency Medicine, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA
                [8 ]Ophirex, Corte Madera, CA, USA
                [9 ]Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
                Author notes
                Correspondence to: E Melnick edward.melnick@ 123456yale.edu (or @Ted_Melnick on Twitter)
                Author information
                https://orcid.org/0000-0002-6509-9537
                Article
                bmj-2021-069271.R2 mele069271
                10.1136/bmj-2021-069271
                9231533
                35760423
                0692ad6e-b6ef-4aaa-9792-609cf758320e
                © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

                This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 18 May 2022
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100000026, National Institute on Drug Abuse;
                Categories
                Research
                1779

                Medicine
                Medicine

                Comments

                Comment on this article